Recent developments with Repligen Corp (RGEN) have led to the company’s beta value being reach 1.25 cents.

A new trading day began on Monday, with Repligen Corp (NASDAQ: RGEN) stock price down -4.62% from the previous day of trading, before settling in for the closing price of $133.41. RGEN’s price has ranged from $113.50 to $184.98 over the past 52 weeks.

A company in the Healthcare sector has jumped its sales by 29.32% annually for the last half of the decade. Meanwhile, its annual earnings per share averaged 8.05%. With a float of $53.02 million, this company’s outstanding shares have now reached $56.09 million.

In an organization with 1778 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 48.69%, operating margin of -6.5%, and the pretax margin is -5.17%.

Repligen Corp (RGEN) Insider and Institutional Ownership

As we move forward, let’s examine how large-scale investors are investing in this stock of the Medical Instruments & Supplies Industry. The insider ownership of Repligen Corp is 5.57%, while institutional ownership is 100.75%. The most recent insider transaction that took place on Mar 17 ’25, was worth 4,080,663. In this transaction Director of this company sold 26,756 shares at a rate of $152.51, taking the stock ownership to the 136,301 shares. Before that another transaction happened on Mar 17 ’25, when Company’s Director bought 250 for $150.69, making the entire transaction worth $37,672. This insider now owns 1,043 shares in total.

Repligen Corp (RGEN) Latest Financial update

Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.42 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around 8.05% per share during the next fiscal year.

Repligen Corp (NASDAQ: RGEN) Trading Performance Indicators

Here are Repligen Corp’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 7.28. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 11.26. Likewise, its price to free cash flow for the trailing twelve months is 49.10.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.46, a number that is poised to hit 0.35 in the next quarter and is forecasted to reach 2.25 in one year’s time.

Technical Analysis of Repligen Corp (RGEN)

Let’s dig in a bit further. During the last 5-days, its volume was 0.78 million. That was better than the volume of 0.66 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 11.26%. Additionally, its Average True Range was 7.59.

During the past 100 days, Repligen Corp’s (RGEN) raw stochastic average was set at 9.38%, which indicates a significant increase from 6.49% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 47.12% in the past 14 days, which was lower than the 53.59% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $153.81, while its 200-day Moving Average is $145.52. However, in the short run, Repligen Corp’s stock first resistance to watch stands at $130.47. Second resistance stands at $133.70. The third major resistance level sits at $136.24. If the price goes on to break the first support level at $124.70, it is likely to go to the next support level at $122.16. The third support level lies at $118.93 if the price breaches the second support level.

Repligen Corp (NASDAQ: RGEN) Key Stats

With a market capitalization of 7.14 billion, the company has a total of 56,149K Shares Outstanding. Currently, annual sales are 634,440 K while annual income is -25,510 K. The company’s previous quarter sales were 174,150 K while its latest quarter income was -30,280 K.